The genetically modified suilysin, rSLYP353L, provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis

•We constructed non-hemolytic rSLYP353L mutant with single amino acid substitute.•The non-hemolytic rSLYP353L elicited reduced inflammatory response in vivo.•Anti-SLYP353L antisera protected mice from acute death after infection with S. suis.•Infected mice death within 24h is not due to obvious pathological damage to organs.•Immunization with rSLYP353L caused reduced inflammatory response to S. suis infection.